Diamyd Logo
This website is only intended for investors

Fighting diabetes

Diamyd Medical is a diabetes company active in the field of pharmaceutical development. The Company is headquartered in Stockholm, Sweden and shares are listed on Nasdaq Stockholm First North (ticker: DMYD B).
Our in-licensed technologies for GAD, GABA and Gliadin, and the investment in stem cells are all very relevant for driving us toward the vision – a cure for type 1 diabetes.
Diabetes is associated with serious complications due to elevated and fluctuating blood sugar levels, causing substantial suffering and extensive costs for society.
Type 1 diabetes is an inflammatory autoimmune disease where the insulin-producing cells are destroyed. A cure for the disease requires: 1) treatment of the inflammation; 2) abrogating of the autoimmunity...
Diamyd® is a GAD-based therapy under development for the treatment and prevention of autoimmune diabetes such as type 1 diabetes and LADA. Treatment with Diamyd® aims to intervene in the...
rss icon
pdf icon
14 oktober 2015, 08:30
Bokslutskommuniké 14/15
Senaste Årsredovisningen
pdf icon
05 november 2015, 13:00
Årsredovisning 14/15